IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene MTAP Ensembl ENSG00000099810 Chromosome 9 Start 21792635 End 22019516
Description S-methyl-5'-thioadenosine phosphorylase (EC 2.4.2.28)(5'-methylthioadenosine phosphorylase)(MTA phosphorylase)(MTAPase) [Source:UniProtKB/Swiss-Prot;Acc:Q13126]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 7413
     Entrez Gene : 4507
     UCSC : uc003zph.2
     GeneCards : 7413
     RefSeq : NM_002451
     CCDS : CCDS6509.1
     Uniprot : Q13126
     Interpro : Q13126
     OMIM : 156540
     GeneTests : MTAP
     CGAP : MTAP
     PMID : 11126361

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  38150_at  0.34  1.22e-1  1.95e-1  0.11  7.24e-1  7.97e-1
 HG_U133A  204956_at  0.22  2.84e-2  4.13e-2  4.78  4.85e-75  1.75e-74
 HG_U133A  211363_s_at  0.75  1.97e-5  4.43e-5  4.30  1.24e-93  7.07e-93
 HG_U133A  211364_at  -0.37  1.92e-10  7.14e-10  -1.38  4.72e-58  1.23e-57
 HG_U133A  216685_s_at  1.03  3.25e-9  1.08e-8  0.97  2.57e-10  3.23e-10
 HG_U133A  217134_at  0.20  1.04e-1  1.36e-1  4.68  3.81e-120  4.63e-119
 HG_U133_Plus2  204956_at  0.10  4.43e-1  5.33e-1  -0.11  5.80e-1  6.35e-1
 HG_U133_Plus2  211363_s_at  0.73  1.50e-3  3.73e-3  0.42  1.22e-1  1.61e-1
 HG_U133_Plus2  211364_at  0.69  5.59e-7  2.63e-6  1.32  5.87e-12  3.26e-11
 HG_U133_Plus2  216685_s_at  0.21  2.72e-1  3.57e-1  0.29  1.54e-1  1.98e-1
 HG_U133_Plus2  217134_at  0.10  5.67e-1  6.49e-1  0.36  7.50e-2  1.04e-1
 HG_U133_Plus2  231984_at  -0.05  7.40e-1  7.99e-1  -0.21  3.26e-1  3.86e-1
 Agilent_HS_21.6K  13524  0.03  5.98e-1  7.52e-1  0.02  7.20e-1  8.18e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  204956_at  -0.67  2.12e-1  8.38e-1  -0.17  5.84e-1  1.00e+0
 HG_U133A  211363_s_at  0.71  1.77e-1  8.20e-1  -0.65  9.60e-2  1.00e+0
 HG_U133A  211364_at  0.04  8.43e-1  9.88e-1  0.02  8.73e-1  1.00e+0
 HG_U133A  216685_s_at  0.47  3.75e-1  8.96e-1  -0.87  2.18e-2  1.00e+0
 HG_U133A  217134_at  -0.39  3.62e-1  8.95e-1  0.07  7.92e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 38150_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 204956_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211363_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211364_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 216685_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 217134_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 204956_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211363_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211364_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 216685_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 217134_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 231984_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 13524    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
mtap tumor Furthermore, in four osteosarcoma patients, an MTAP deletion which was not evident at diagnosis was detected in subsequent tumor samples. 11895909 Human
mtap tumors CONCLUSIONS: The MTAP gene is commonly deleted in osteosarcoma patient samples, leading to an absence of mRNA and protein expression; these results indicate that inhibitors of de novo purine synthesis or methionine depletion may be effective as treatments 11895909 Human
mtap tumors The idea of the chemoselectivity concept is that tumors with MTAP deletion at chromosome 9p21 are more susceptible to antimetabolites than normal cells without such a deletion. 11987241 Human
methylthioadenosine phosphorylase adult t-cell leukemia Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). 12200696 Human
mtap adult t-cell leukemia Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). 12200696 Human
mtap adult t-cell leukemia We reported previously that the MTAP gene is deleted in adult T cell leukemia (ATL) cells. 12200696 Human
methylthioadenosine phosphorylase breast cancer Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. 12438261 Human
methylthioadenosine phosphorylase human tumors The human methylthioadenosine phosphorylase (MTAP) gene is located on 9p21 and is frequently homozygously deleted, along with p16(cdkN2a/ARF), in a wide variety of human tumors and human tumor-derived cell lines. 12438261 Human
mtap human tumors The human methylthioadenosine phosphorylase (MTAP) gene is located on 9p21 and is frequently homozygously deleted, along with p16(cdkN2a/ARF), in a wide variety of human tumors and human tumor-derived cell lines. 12438261 Human
mtap breast adenocarcinoma We have reintroduced MTAP into MCF-7 breast adenocarcinoma cells and have examined its effect on the tumorigenic properties of these cells. 12438261 Human
methylthioadenosine phosphorylase t-cell acute lymphoblastic leukemia Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. 10803528 Human
mtap t-cell acute lymphoblastic leukemia Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. 10803528 Human
methylthioadenosine phosphorylase tumors Methylthioadenosine phosphorylase (MTAP) deficiency in tumors can be therapeutically exploited for selective therapy. 10803528 Human
mtap tumors Methylthioadenosine phosphorylase (MTAP) deficiency in tumors can be therapeutically exploited for selective therapy. 10803528 Human
mtap tumors Many tumors lacking MTAP have been found to homozygously delete the chromosome 9p region containing the p16 tumor suppressor gene. 10803528 Human
mtap tumor Many tumors lacking MTAP have been found to homozygously delete the chromosome 9p region containing the p16 tumor suppressor gene. 10803528 Human
methylthioadenosine phosphorylase tumor Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. 11034100 Human
methylthioadenosine phosphorylase cancer A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. 11126361 Human
mtap cancer A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. 11126361 Human
mtap glioma Here we describe the partial sequence and the exact localization of a new gene on chromosome 9p21 centromeric of p15INK4B, that formed an in frame fusion transcript with MTAP in a glioma xenograft, and that is homozygously deleted in various malignant cel 11126361 Human
methylthioadenosine phosphorylase cancers Methylthioadenosine phosphorylase (MTAP) is an important enzyme for the salvage of adenine and methionine and is deficient in a variety of cancers including T-cell acute lymphocytic leukemia (T-ALL). 10197619 Human
mtap cancers Methylthioadenosine phosphorylase (MTAP) is an important enzyme for the salvage of adenine and methionine and is deficient in a variety of cancers including T-cell acute lymphocytic leukemia (T-ALL). 10197619 Human
mtap tumors Quantitative PCR showed chromosome 9p deletions including p16 tumor suppressor gene (2 of 7 tumors) and MTAP gene (3 of 7). 10329596 Human
mtap tumor Quantitative PCR showed chromosome 9p deletions including p16 tumor suppressor gene (2 of 7 tumors) and MTAP gene (3 of 7). 10329596 Human
mesado phosphorylase murine sarcoma The substrate specificity of trypanosomal MeSAdo/Ado phosphorylase differed from that of a mammalian MeSAdo phosphorylase (derived from murine Sarcoma 180 cells) in that it was able to phosphorolyze 2'-deoxyadenosine, 3'-deoxyadenosine and 2&apo 3125430 Human
methylthioadenosine phosphorylase acute leukemia Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features. 3130904 Human
methylthioadenosine phosphorylase acute leukemia Blast cells from 100 cases of acute leukemia were evaluated for the presence of methylthioadenosine phosphorylase (MTAase), an enzyme important in polyamine metabolism. 3130904 Human
mesado phosphorylase human tumors Furthermore, a substantial number of human tumors are deficient in MeSAdo phosphorylase, and cannot degrade MeSAdo. 3102048 Human
methylthioadenosine phosphorylase adult t-cell leukemia The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. 9426690 Human
methylthioadenosine phosphorylase tumor The gene for methylthioadenosine phosphorylase (MTAP), a purine and methionine metabolic enzyme, resides approximately 100 Kb telomeric to the p16INK4a gene and is frequently co-deleted with the tumor suppressor gene in a variety of cancers. 9426690 Human
mtap tumor The gene for methylthioadenosine phosphorylase (MTAP), a purine and methionine metabolic enzyme, resides approximately 100 Kb telomeric to the p16INK4a gene and is frequently co-deleted with the tumor suppressor gene in a variety of cancers. 9426690 Human
methylthioadenosine phosphorylase cancers The gene for methylthioadenosine phosphorylase (MTAP), a purine and methionine metabolic enzyme, resides approximately 100 Kb telomeric to the p16INK4a gene and is frequently co-deleted with the tumor suppressor gene in a variety of cancers. 9426690 Human
mtap cancers The gene for methylthioadenosine phosphorylase (MTAP), a purine and methionine metabolic enzyme, resides approximately 100 Kb telomeric to the p16INK4a gene and is frequently co-deleted with the tumor suppressor gene in a variety of cancers. 9426690 Human
mtap large-cell lymphoma Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. 9591637 Human
mtap non-hodgkin's lymphoma Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. 9591637 Human
mtap tumor Recently, we and others have defined a tumor suppressor region on the short arm of chromosome 9 harboring a cluster of genes, including MTAP, CDKN2A (p16INK4a), and CDKN2B (p15INK4B), which is frequently deleted in a variety of tumor types. 9591637 Human
mtap endometrial cancer MTAP gene deletion in endometrial cancer. 9623796 Human
mtap cancers Cancers with deletions of the MTAP gene may be especially susceptible to chemotherapeutic regimes which interfere with purine or methionine utilization. 9623796 Human
mtap endometrial cancer The purpose of this study was to determine deletion of the MTAP gene in endometrial cancer using a polymerase chain reaction-based method. 9623796 Human
mtap cancers Partial or total deletions of the MTAP gene were detected in 7 (14%) of these cancers. 9623796 Human
mtap endometrial cancer The findings indicate that deletion of the MTAP gene does occur in a subgroup of endometrial cancer. 9623796 Human
mtap other cancers The present work may be extended to the development of molecular diagnosis of MTAP gene deletion in other cancers and assist in selecting appropriate chemotherapy. 9623796 Human
methylthioadenosine phosphorylase human tumors The gene encoding methylthioadenosine phosphorylase (MTAP), the initial enzyme in the methionine salvage pathway, is deleted in a variety of human tumors and acts as a tumor suppressor gene in cell culture (Christopher, S. A., Diegelman, P., Porter, C. W. 14506228 Human
mtap human tumors The gene encoding methylthioadenosine phosphorylase (MTAP), the initial enzyme in the methionine salvage pathway, is deleted in a variety of human tumors and acts as a tumor suppressor gene in cell culture (Christopher, S. A., Diegelman, P., Porter, C. W. 14506228 Human
methylthioadenosine phosphorylase tumor The gene encoding methylthioadenosine phosphorylase (MTAP), the initial enzyme in the methionine salvage pathway, is deleted in a variety of human tumors and acts as a tumor suppressor gene in cell culture (Christopher, S. A., Diegelman, P., Porter, C. W. 14506228 Human
mtap tumor The gene encoding methylthioadenosine phosphorylase (MTAP), the initial enzyme in the methionine salvage pathway, is deleted in a variety of human tumors and acts as a tumor suppressor gene in cell culture (Christopher, S. A., Diegelman, P., Porter, C. W. 14506228 Human
mtap breast adenocarcinoma Expression of MTAP in MTAP-deleted MCF-7 breast adenocarcinoma cells results in a significant reduction of ODC activity and reduction in polyamine levels. 14506228 Human
mtap human tumors Taken together, our results show that products of the methionine salvage pathway regulate polyamine biosynthesis and suggest that MTAP deletion may lead to ODC activation in human tumors. 14506228 Human
methylthioadenosine phosphorylase other tumors MTAP, a gene approximately 100-kb telomeric to CDKN2A, encodes methylthioadenosine phosphorylase, an enzyme essential in the salvage of cellular adenine and methionine, and its codeletion with CDKN2A has been reported in other tumors. 12796375 Human
mtap pleural mesothelioma The aim of this study was to define the prevalence of homozygous deletion of CDKN2A alone or in combination with MTAP in a large series of pleural mesothelioma. 12796375 Human
mtap pleural mesothelioma EXPERIMENTAL DESIGN: We used a fluorescent in situ hybridization assay for CDKN2A and MTAP on interphase nuclei in imprints of frozen tissue from 95 cases of pleural mesothelioma. 12796375 Human
mtap mesothelioma Thus, the particularly high prevalence of MTAP codeletion in mesothelioma makes it an ideal candidate for trials of targeted therapy using inhibitors of de novo AMP synthesis (e.g., L-alanosine). 12796375 Human
methylthioadenosine phosphorylase non-small cell lung cancers Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). 9840931 Human
mtap non-small cell lung cancers Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). 9840931 Human
methylthioadenosine phosphorylase non-small cell lung cancer Homozygous deletions of the tumor suppressor gene p16INK4A and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). 9840931 Human
mtap non-small cell lung cancer Homozygous deletions of the tumor suppressor gene p16INK4A and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). 9840931 Human
methylthioadenosine phosphorylase cancer Human methylthioadenosine phosphorylase (MTAP) is a purine and methionine metabolic enzyme present ubiquitously in all normal tissues, but often deleted in many types of cancer. 9074505 Human
mtap cancer Human methylthioadenosine phosphorylase (MTAP) is a purine and methionine metabolic enzyme present ubiquitously in all normal tissues, but often deleted in many types of cancer. 9074505 Human
mtap tumor The gene encoding MTAP, MTAP, is frequently codeleted along with the tumor suppressor gene p16 in malignant cells bearing homozygous deletions in the chromosome 9p21 region. p16-, MTAP- malignant cells have been shown to be more susceptible to the purine 9351982 Human
mtap other cancers In addition, MTAP deficiency has been reported in other cancers. 9815702 Human
mtap cancer Thus, MTAP deficiency in cancer may offer opportunities for developing selective therapy, which would spare normal cells. 9815702 Human
methylthioadenosine phosphorylase bladder carcinomas In this study, 27 malignant cell lines, including leukemias, gliomas, and lung and bladder carcinomas were screened for homozygous deletions of the putative tumor suppressor gene p16 (MTS1/CDK4I/CDKN2) and other markers within the chromosome 9p21 region; 8616780 Human
mtap bladder carcinomas In this study, 27 malignant cell lines, including leukemias, gliomas, and lung and bladder carcinomas were screened for homozygous deletions of the putative tumor suppressor gene p16 (MTS1/CDK4I/CDKN2) and other markers within the chromosome 9p21 region; 8616780 Human
methylthioadenosine phosphorylase cancers Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. 8650244 Human
mtap cancers MTAP is abundant in normal cells but is deficient in many cancers. 8650244 Human
mtap cancer However, the order of the MTAP, p16, p15, and IFNA genes on chromosome 9p is uncertain, and the molecular basis for MTAP deficiency in cancer is unknown. 8650244 Human
mtap cancer These results indicate that MTAP deficiency in cancer is primarily due to codeletion of the MTAP and p16 genes. 8650244 Human
mtap pancreatic carcinoma Five of the eight pancreatic carcinoma cell lines were p16(-), MTAP was codeleted in all five cases. 8640765 Human
mtap chondrosarcoma Molecular analysis of these chondrosarcoma cell lines revealed hemizygous deletions of the interferon genes, and the absence of the MTAP gene, protein or activity. 8689637 Human
methylthioadenosine phosphorylase tumors The methylthioadenosine phosphorylase (MTAP) gene gained considerable interest as therapeutic target for tumors with the 9p21 deletion. 12906926 Human
mtap tumors The methylthioadenosine phosphorylase (MTAP) gene gained considerable interest as therapeutic target for tumors with the 9p21 deletion. 12906926 Human
mtap tumors This gene maps to 9p21 and loss of this chromosomal region in tumors offers an unique opportunity for chemoselective treatment, since MTAP is an important salvage enzyme for the formation of adenine that is needed for DNA synthesis. 12906926 Human
mtap tumor L-Alanosine, an antibiotic from Streptomyces alanosinicus, blocks the common de novo purine biosynthesis pathway and, thereby, inhibits tumor cells with MTAP deficiency. 12906926 Human
mtap tumor The present analysis was undertaken to gain insights into the molecular architecture of tumor cells that determines the response to L-alanosine apart from the MTAP gene. 12906926 Human
mtap bladder cancer The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. 8873383 Human
mtap bladder cancer To more clearly determine the effect of these 9p21 alterations, we mapped the homozygous deletions and performed a detailed mutational and expression analysis for CDKN2, CDKN2B and a closely linked gene, methylthioadenoside phosphorylase (MTAP), in 16 est 8873383 Human
methylthioadenosine phosphorylase t-cell acute lymphoblastic leukemia Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. 8874207 Human
methylthioadenosine phosphorylase cancers Methylthioadenosine phosphorylase (MTAP), an enzyme essential for the salvage of adenine and methionine, is deficient in a variety of cancers, including acute lymphoblastic leukemia (ALL). 8874207 Human
mtap cancers Methylthioadenosine phosphorylase (MTAP), an enzyme essential for the salvage of adenine and methionine, is deficient in a variety of cancers, including acute lymphoblastic leukemia (ALL). 8874207 Human
methylthioadenosine phosphorylase lung cancer Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. 8971171 Human
methylthioadenosine phosphorylase cancers Methylthioadenosine phosphorylase (MTAP), an enzyme involved in purine and methionine metabolism, is present in all normal tissues but is frequently deficient in a variety of cancers. 8971171 Human
mtap cancers Methylthioadenosine phosphorylase (MTAP), an enzyme involved in purine and methionine metabolism, is present in all normal tissues but is frequently deficient in a variety of cancers. 8971171 Human
mtap lung cancer MTAP-negative A549 lung cancer cells were transfected with eukaryotic expression vectors encoding MTAP cDNA in sense and antisense orientations. 8971171 Human
mtap cancer These results prove that MTAP deficiency contributes directly to the sensitivity of cancer cells to purine or methionine depletion. 8971171 Human
mtap multiple tumor The gene (MTAP) encoding this enzyme was previously mapped to the short arm of chromosome 9, band p21-22, a region that is frequently deleted in multiple tumor types. 7604019 Human
methylthioadenosine phosphorylase b-chronic lymphocytic leukemia Methylthioadenosine phosphorylase and purine nucleoside phosphorylase in B-chronic lymphocytic leukemia. 6441319 Human
methylthioadenosine phosphorylase human breast cancer Methylthioadenosine phosphorylase in human breast cancer. 3109530 Human
5'-methylthioadenosine phosphorylase tumor The 5'-deoxy-5'-iodo-substituted analogs of adenosine and inosine are cytotoxic to tumor cells that have high activities of 5'-methylthioadenosine phosphorylase and purine nucleoside phosphorylase, respectively (Savarese, T.M., Chu, S-H., C 2934389 others
5'-methylthioadenosine phosphorylase lymphocytic leukemia The two lines are murine lymphocytic leukemia cells which differ in their ability to metabolize 5'-methylthioadenosine, the by-product of polyamine biosynthesis: L5178Y cells contain a specific 5'-methylthioadenosine phosphorylase; L1210 cells d 3080234 Mouse
methylthioadenosine phosphorylase human leukemias Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors. 3093064 Human
mesado phosphorylase murine sarcoma The 2-halogenated derivatives of acyloadenosine [9-(2-hydroxyethoxy-methyl)adenine], including the chloro-, bromo- and iodo-congeners, all inhibited murine Sarcoma 180 (S180) MeSAdo phosphorylase, with Ki values in the range of 10(-6) to 10(-5) M. 2125222 Human
methylthioadenosine phosphorylase cancers The minimal deletion shared by the latter three cancers extends from the interferon-alpha locus towards the centromere; its centromeric end is flanked by the gene encoding methylthioadenosine phosphorylase. 8275465 Human
methylthioadenosine phosphorylase melanoma We have determined that the telomeric end of the minimal homozygous deletion shared by two melanoma cell lines does not include the methylthioadenosine phosphorylase locus. 8275465 Human
mtap childhood acute lymphoblastic leukemia CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. 12661005 Human
methylthioadenosine phosphorylase non-small cell lung cancers Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. 8382555 Human
mesado phosphorylase non-small cell lung cancers Our data suggest that MeSAdo phosphorylase deficiency is frequently found in non-small cell lung cancers and can be exploited in designing enzyme-selective chemotherapy. 8382555 Human
mtap acute lymphoblastic leukemia Recent evidence suggests that homozygous loss of the interferon (IFN) and methylthioadenosine phosphorylase (MTAP) genes located on 9p and a tumor suppressor gene closely linked to them is associated with acute lymphoblastic leukemia and with gliomas. 7683574 Human
methylthioadenosine phosphorylase acute lymphoblastic leukemia Recent evidence suggests that homozygous loss of the interferon (IFN) and methylthioadenosine phosphorylase (MTAP) genes located on 9p and a tumor suppressor gene closely linked to them is associated with acute lymphoblastic leukemia and with gliomas. 7683574 Human
mtap lung cancer Overall, 24 of 56 (43%) lung cancer cell lines examined had hemizygous or homozygous loss of DNA sequences which include the IFN or MTAP genes. 7683574 Human
mtap human tumor Some mouse and human tumor cells lack MTAP activity and can not grow in the presence of azaserine and MTA. 7507266 Human
mtap tumors Our current results map the shortest region of overlap of these deletions in the various tumors to the region between the centromeric end of the IFNA/IFNW gene cluster and the MTAP gene locus. 1385305 Human
methylthioadenosine phosphorylase human leukemias A complete deficiency of methylthioadenosine phosphorylase has been reported in some human leukemias and lymphomas and in a few solid tumors. 1904005 Human
methylthioadenosine phosphorylase human leukemias Abnormalities of chromosome 9p have been reported in human leukemias and lymphomas, and in cell lines lacking the enzyme methylthioadenosine phosphorylase. 1879830 Human
methylthioadenosine phosphorylase glioma Molecular genetic analysis of chromosome 9p in methylthioadenosine phosphorylase deficient glioma cell lines. 1781369 Human
mtap malignant melanoma Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. 12875987 Human
mtap malignant melanomas The aim of this study was to analyze MTAP mutations and expression patterns in malignant melanomas. 12875987 Human
mtap melanoma To examine the MTAP gene and expression of MTAP protein we screened 9 human melanoma cell lines and primary human melanocytes by reverse transcriptase-polymerase chain reaction, sequencing, and immunoblotting. 12875987 Human
mtap melanoma Analyzing the melanoma cell lines we found significant down-regulation of MTAP mRNA expression. 12875987 Human
mtap melanoma MTAP expression was further analyzed in vivo by immunohistochemical staining of 38 tissue samples of benign melanocytic nevi, melanomas, and melanoma metastases. 12875987 Human
mtap melanomas MTAP expression was further analyzed in vivo by immunohistochemical staining of 38 tissue samples of benign melanocytic nevi, melanomas, and melanoma metastases. 12875987 Human
mtap benign melanocytic nevi MTAP expression was further analyzed in vivo by immunohistochemical staining of 38 tissue samples of benign melanocytic nevi, melanomas, and melanoma metastases. 12875987 Human
mtap metastases MTAP expression was further analyzed in vivo by immunohistochemical staining of 38 tissue samples of benign melanocytic nevi, melanomas, and melanoma metastases. 12875987 Human
mtap metastatic melanomas In summary, we demonstrate significant inverse correlation between MTAP protein expression and progression of melanocytic tumors as the amount of MTAP protein staining decreases from benign melanocytic nevi to metastatic melanomas. 12875987 Human
mtap benign melanocytic nevi In summary, we demonstrate significant inverse correlation between MTAP protein expression and progression of melanocytic tumors as the amount of MTAP protein staining decreases from benign melanocytic nevi to metastatic melanomas. 12875987 Human
mtap tumors In summary, we demonstrate significant inverse correlation between MTAP protein expression and progression of melanocytic tumors as the amount of MTAP protein staining decreases from benign melanocytic nevi to metastatic melanomas. 12875987 Human
mtap melanomas Our results suggest an important role of MTAP inactivation in the development of melanomas. 12875987 Human
methylthioadenosine phosphorylase acute lymphoblastic leukemia As determined by autoradiography of viable cells, and by direct enzymatic analysis, samples from one individual with pre-T-cell acute lymphoblastic leukemia and one with common acute lymphoblastic leukemia were methylthioadenosine phosphorylase deficient. 6814551 Human
methylthioadenosine phosphorylase common acute lymphoblastic leukemia As determined by autoradiography of viable cells, and by direct enzymatic analysis, samples from one individual with pre-T-cell acute lymphoblastic leukemia and one with common acute lymphoblastic leukemia were methylthioadenosine phosphorylase deficient. 6814551 Human
methylthioadenosine phosphorylase malignant tumor Seven out of 31 (23%) human malignant tumor cell lines had no detectable methylthioadenosine phosphorylase activity (less than 0.001 nmol/min per mg of protein), assayed with 5'-chloroadenosine as substrate. 6785752 Human
methylthioadenosine phosphorylase malignant tumor Thus, human malignant tumor cell lines naturally deficient in methylthioadenosine phosphorylase could be selectively killed when de novo purine synthesis was inhibited and methylthioadenosine was the only exogenous source of purines. 6785752 Human
methylthioadenosine phosphorylase solid tumors Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors. 3093064 Human
methylthioadenosine phosphorylase gliomas Absence of methylthioadenosine phosphorylase in human gliomas. 1904005 Human
methylthioadenosine phosphorylase solid tumors A complete deficiency of methylthioadenosine phosphorylase has been reported in some human leukemias and lymphomas and in a few solid tumors. 1904005 Human
methylthioadenosine phosphorylase gliomas Seventy-five % (9 of 12) of the gliomas were completely methylthioadenosine phosphorylase deficient. 1904005 Human
methylthioadenosine phosphorylase gliomas Recent evidence suggests that homozygous loss of the interferon (IFN) and methylthioadenosine phosphorylase (MTAP) genes located on 9p and a tumor suppressor gene closely linked to them is associated with acute lymphoblastic leukemia and with gliomas. 7683574 Human
methylthioadenosine phosphorylase gliomas In this study, 27 malignant cell lines, including leukemias, gliomas, and lung and bladder carcinomas were screened for homozygous deletions of the putative tumor suppressor gene p16 (MTS1/CDK4I/CDKN2) and other markers within the chromosome 9p21 region; 8616780 Human
methylthioadenosine phosphorylase nsclc Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). 9840931 Human
methylthioadenosine phosphorylase nsclc Homozygous deletions of the tumor suppressor gene p16INK4A and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). 9840931 Human
methylthioadenosine phosphorylase solid tumors Cells from 20 patients with leukemia and 9 with solid tumors were assayed for the enzyme methylthioadenosine phosphorylase, which function in both purine and polyamine metabolism in rapidly dividing cells. 6814551 Human
methylthioadenosine phosphorylase pleural mesotheliomas Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. 12796375 Human
methylthioadenosine phosphorylase tumors Tumors with codeletion of the methylthioadenosine phosphorylase gene, as a consequence of p16 deletions, may be particularly sensitive to pemetrexed. 15117425 Human
methylthioadenosine phosphorylase human soft tissue sarcoma Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. 15301428 Human
methylthioadenosine phosphorylase human soft tissue sarcoma The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
methylthioadenosine phosphorylase soft-tissue sarcomas The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
methylthioadenosine phosphorylase fresh tumor The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
methylthioadenosine phosphorylase non-small cell lung cancer [Expression and clinical significance of methylthioadenosine phosphorylase gene in patients with non-small cell lung cancer] OBJECTIVE: To investigate the change of expression of methylthioadenosine phosphorylase (MTAP) gene in patients with non-small cel 15329275 Human
methylthioadenosine phosphorylase pancreatic cancer Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. 15534104 Human
methylthioadenosine phosphorylase cancers PURPOSE: Loss of the methylthioadenosine phosphorylase (MTAP) gene at 9p21 is observed frequently in a variety of human cancers. 15534104 Human
methylthioadenosine phosphorylase human colon carcinoma Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin. 15492751 Human
methylthioadenosine phosphorylase tumors Methylthioadenosine phosphorylase (MTAP) involved in the metabolism of purine and polyamine has been known to be deficient in a variety of tumors. 15753993 Human
methylthioadenosine phosphorylase tumors Tumors lacking methylthioadenosine phosphorylase are sensitive to inhibitors of de novo adenosine synthesis (SDX-102) since they lack a salvage pathway. 15853584 Human
methylthioadenosine phosphorylase tumors The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of d 15950811 Human
methylthioadenosine phosphorylase mesotheliomas The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of d 15950811 Human
mtap gliomas Recent evidence suggests that homozygous loss of the interferon (IFN) and methylthioadenosine phosphorylase (MTAP) genes located on 9p and a tumor suppressor gene closely linked to them is associated with acute lymphoblastic leukemia and with gliomas. 7683574 Human
mtap gliomas In this study, 27 malignant cell lines, including leukemias, gliomas, and lung and bladder carcinomas were screened for homozygous deletions of the putative tumor suppressor gene p16 (MTS1/CDK4I/CDKN2) and other markers within the chromosome 9p21 region; 8616780 Human
mtap t-all Because the MTAP gene is located adjacent to the tumor-suppressor gene p16 on chromosome 9p21 and more than 60% of T-cell ALL (T-ALL) patients have deletion in the p16 gene, we examined the status of the MTAP gene in T-ALL patients. 8874207 Human
mtap t-all The finding of frequent deficiency of MTAP in T-ALL offers the possibility of an enzyme targeted therapy for T-ALL. 8874207 Human
mtap t-all These findings suggest the possibility of targeting MTAP for selective therapy of T-ALL. 8874207 Human
mtap t-all We also compared the effects of L-alanosine and 5'-deoxyadenosine on MTAP (+) and MTAP (-) T-ALL cell lines. 9815702 Human
mtap t-all Therefore, our findings demonstrate the presence of MTAP in human hematopoietic stem/progenitor cells and support the possibility of targeting MTAP in the design of an enzyme-selective therapy for T-ALL and other MTAP-deficient malignancies. 9815702 Human
mtap nsclc Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). 9840931 Human
mtap nsclc Homozygous deletions of the tumor suppressor gene p16INK4A and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). 9840931 Human
mtap nsclc Homozygous deletions of MTAP exon 8 could be detected in 19 of 50 NSCLC samples (38%). 9840931 Human
mtap nsclc These data show a high frequency of homozygous MTAP deletions in NSCLC which is associated with detectable co-deletion of p16INK4A in only half of the cases. 9840931 Human
mtap t-all Homozygous deletions of MTAP and p16 genes were detected respectively in six (20.7%) and eight (27.6%) of 29 ATL samples and in 15 (38.5%) and 23 (59%) of 39 T-ALL samples. 10803528 Human
mtap t-all Previously, we reported that the MTAP gene was deleted in over 30% of T-ALL patients at both diagnosis and relapse. 10197619 Human
mtap t-all Furthermore, normal lymphocytes and MTAP+ primary T-ALL cells were rescued from L-alanosine toxicity by the MTAP substrate 5'-deoxyadenosine, but MTAP-T-ALL cells were not. 10197619 Human
mtap t-all Pretherapeutical detection of 9p21 and MTAP deletion may be helpful in developing a predictive molecular chemosensitivity test for T-ALL. 11987241 Human
mtap other tumors MTAP, a gene approximately 100-kb telomeric to CDKN2A, encodes methylthioadenosine phosphorylase, an enzyme essential in the salvage of cellular adenine and methionine, and its codeletion with CDKN2A has been reported in other tumors. 12796375 Human
mtap pleural mesotheliomas CONCLUSIONS: Homozygous deletion of CDKN2A is seen in the majority of pleural mesotheliomas, and MTAP is codeleted in most of these cases. 12796375 Human
mtap soft-tissue sarcomas The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
mtap fresh tumor The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
mtap fresh tumor We used a polyclonal antibody to measure the expression of MTAP in soft tissue sarcoma cell lines and in fresh tumor samples. 15301428 Human
mtap soft-tissue sarcoma We used a polyclonal antibody to measure the expression of MTAP in soft tissue sarcoma cell lines and in fresh tumor samples. 15301428 Human
mtap tumors MTAP was not expressed in 8 of 21 fresh STS tumors. 15301428 Human
mtap soft-tissue sarcoma The expression of MTAP was also not detectable in 3 of the 11 soft tissue sarcoma cell lines (HT-1080, HS42, and M-9 110). 15301428 Human
mtap tumors An in vivo study using HT-1080 cell tumors with and without MTAP expression confirmed that tumors lacking MTAP were more sensitive to L-alanosine than tumors expressing MTAP. 15301428 Human
mtap cell tumors An in vivo study using HT-1080 cell tumors with and without MTAP expression confirmed that tumors lacking MTAP were more sensitive to L-alanosine than tumors expressing MTAP. 15301428 Human
mtap lung cancer CONCLUSION: The low expression or loss of MTAP gene may be relevant closely to the differentiation degree in lung cancer. 15329275 Human
mtap tumours Hemizygous deletion of the region harbouring the CDKN2A and CDKN2B loci was identified in two tumours by means of fluorescent in situ hybridisation and MTAP was present by immunostaining in all but one tumour analysed. 15305192 Human
mtap tumour Hemizygous deletion of the region harbouring the CDKN2A and CDKN2B loci was identified in two tumours by means of fluorescent in situ hybridisation and MTAP was present by immunostaining in all but one tumour analysed. 15305192 Human
mtap tumor Given the recently proposed tumor suppressor activity of MTAP, our observations can be relevant to the elucidation of the molecular mechanisms of multistep hepatocarcinogenesis. 15511635 Human
mtap cancers PURPOSE: Loss of the methylthioadenosine phosphorylase (MTAP) gene at 9p21 is observed frequently in a variety of human cancers. 15534104 Human
mtap pancreatic tumor The aim of this study is to analyze MTAP and ornithine decarboxylase (ODC) expression in primary pancreatic tumor specimens. 15534104 Human
mtap tumor EXPERIMENTAL DESIGN: We measured MTAP and ODC activity in protein extracts derived from 30 surgically resected tumor samples and eight normal pancreas samples. 15534104 Human
mtap neuroendocrine tumors Result: MTAP activity was 2.8-fold reduced in adenocarcinomas and 6.3-fold reduced in neuroendocrine tumors compared with control pancreas. 15534104 Human
mtap tumor Using interphase fluorescence in situ hybridization, we found in tumor samples that 43 to 75% of the nuclei had lost at least one copy of MTAP locus, indicating that loss of MTAP activity was at least partially because of deletion of the MTAP locus. 15534104 Human
mtap neuroendocrine tumors CONCLUSIONS: MTAP activity is frequently lost, and ODC activity is frequently elevated in both pancreatic adenocarcinoma and neuroendocrine tumors. 15534104 Human
mtap pancreatic adenocarcinoma CONCLUSIONS: MTAP activity is frequently lost, and ODC activity is frequently elevated in both pancreatic adenocarcinoma and neuroendocrine tumors. 15534104 Human
mtap pancreatic cancer These findings suggest that MTAP and polyamine metabolism could be potential therapeutic targets in the treatment of pancreatic cancer. 15534104 Human
mtap melanomas Interestingly, we detected no methylation of MGMT, PTEN, MTAP and p27, which were previously reported as silenced in melanomas. 15596045 Human
mtap human colon carcinoma Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin. 15492751 Human
mtap cancer The MTAP gene is localized on the human chromosomal region 9p21, a region often deleted in cancer. 15492751 Human
mtap colon carcinoma The aim of this study was to analyse the role of MTAP in colon carcinoma and normal colon epithelium and the regulation of gene expression. 15492751 Human
mtap colon carcinoma To examine MTAP RNA and protein expression, we screened six colon carcinoma cell lines and human primary colon epithelial cells by RT-PCR and immunoblotting. 15492751 Human
mtap adenoma MTAP expression was confirmed in vivo by immunohistochemical staining of normal colon tissue compared to adenoma and colon carcinoma. 15492751 Human
mtap colon carcinoma MTAP expression was confirmed in vivo by immunohistochemical staining of normal colon tissue compared to adenoma and colon carcinoma. 15492751 Human
mtap colon carcinoma Interestingly, we found strong MTAP mRNA and protein expression by colon carcinoma cell lines but no expression by colonic epithelial cells. 15492751 Human
mtap tumour Furthermore, we demonstrated a significant correlation between MTAP protein expression and tumour progression as the intensity of MTAP protein staining increased from normal tissue to carcinoma. 15492751 Human
mtap carcinoma Furthermore, we demonstrated a significant correlation between MTAP protein expression and tumour progression as the intensity of MTAP protein staining increased from normal tissue to carcinoma. 15492751 Human
mtap carcinoma In addition, the recently postulated association between MTAP activity and interferon (IFN) sensitivity was confirmed in colon epithelial cells showing only little response to IFN-gamma, in contrast to the carcinoma cell lines. 15492751 Human
mtap colon carcinoma In summary, these data indicate for the first time that MTAP is not expressed in normal human colonic epithelium but is strongly upregulated in colon carcinoma. 15492751 Human
mtap tumors Methylthioadenosine phosphorylase (MTAP) involved in the metabolism of purine and polyamine has been known to be deficient in a variety of tumors. 15753993 Human
mtap adult t-cell leukemia Promoter methylation of the MTAP gene was also found in DNA samples from adult T-cell leukemia patients. 15753993 Human
mtap malignancy These results indicated that promoter hypermethylation is another mechanism of MTAP deficiency in human malignancy. 15753993 Human
mtap invasive adenocarcinoma Homozygous Deletion of the MTAP Gene In Invasive Adenocarcinoma of the Pancreas and in Periampullary Cancer: A Potential New Target for Therapy. 15662124 Human
mtap cancers Novel chemotherapeutic strategies exploiting the selective loss of MTAP function in cancers have been proposed. 15662124 Human
mtap pancreatic cancers Biallelic deletions of the p16INK4A/CDKN2A gene are found in 40% of pancreatic cancers, suggesting that the MTAP gene may be frequently inactivated in pancreatic cancer and that selected patients with pancreatic cancer may benefit from therapies targeting 15662124 Human
mtap pancreatic cancer Biallelic deletions of the p16INK4A/CDKN2A gene are found in 40% of pancreatic cancers, suggesting that the MTAP gene may be frequently inactivated in pancreatic cancer and that selected patients with pancreatic cancer may benefit from therapies targeting 15662124 Human
mtap pancreatic cancers We immunolabeled six xenografted pancreatic cancers with known MTAP and p16INK4A/CDKN2A gene status and found that immunolabeling mirrored gene status. 15662124 Human
mtap pancreatic cancers Loss of expression of both MTAP and p16 was observed only in those pancreatic cancers with homozygous deletions that encompassed both the MTAP and p16INK4A/CDKN2A genes. 15662124 Human
mtap pancreatic cancers Immunolabeling for MTAP was lost in 91 of the 300 (30%) evaluable pancreatic cancers, 9 of 54 (17%) ampullary cancers, 4 of 33 (12%) biliary cancers, and in 1 of 35 (3%) IPMNs. 15662124 Human
mtap ampullary cancers Immunolabeling for MTAP was lost in 91 of the 300 (30%) evaluable pancreatic cancers, 9 of 54 (17%) ampullary cancers, 4 of 33 (12%) biliary cancers, and in 1 of 35 (3%) IPMNs. 15662124 Human
mtap pancreatic cancers These results suggest that MTAP expression is lost in approximately 30% of infiltrating pancreatic cancers and in a lower percentage of other periampullary neoplasms, that this loss is the result of homozygous deletions encompassing both the MTAP and p16I 15662124 Human
mtap cancer Thus, pancreatic cancer is a promising cancer type in which to explore novel chemotherapeutic strategies to exploit the selective loss of MTAP function. 15662124 Human
mtap pancreatic cancer Thus, pancreatic cancer is a promising cancer type in which to explore novel chemotherapeutic strategies to exploit the selective loss of MTAP function. 15662124 Human
mtap tumors The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of d 15950811 Human
mtap mesotheliomas The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of d 15950811 Human
mtap pancreatic intraepithelial neoplasia Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. 15832197 Human
mtap panin Here we immunolabeled a series of pancreatic intraepithelial neoplasia (PanIN) lesions of various histologic grades for the p16 and MTAP gene products using a high-throughput PanIN tissue microarray (TMA) format. 15832197 Human
mtap pancreatic intraepithelial neoplasia Here we immunolabeled a series of pancreatic intraepithelial neoplasia (PanIN) lesions of various histologic grades for the p16 and MTAP gene products using a high-throughput PanIN tissue microarray (TMA) format. 15832197 Human
methylthioadenosine phosphorylase all These findings indicate that loss of chromosomal material in the region of 9p21-p22 is closely associated with lymphomatous ALL; by analogy with retinoblastoma, in which gene deletions are associated with an enzyme deficiency, this disease may be related 3925340 Human
methylthioadenosine phosphorylase b-chronic lymphocytic leukemia (b-cll) The activity of two of them, methylthioadenosine phosphorylase (MTA phosphorylase) and purine nucleoside phosphorylase (PNP) were measured in peripheral mononuclear cells from 11 patients with B-chronic lymphocytic leukemia (B-CLL) and compared with those 6441319 Human
5'-methylthioadenosine phosphorylase sarcoma 180 The analog sugar phosphate inhibited purine nucleoside phosphorylase from human erythrocytes, phosphoglucomutase from rabbit muscle, and 5'-methylthioadenosine phosphorylase from Sarcoma 180 cells with Ki values of 26, 100, and 9 microM, respectively 2934389 Human
methylthioadenosine phosphorylase acute lymphoblastic leukemia (all) Methylthioadenosine phosphorylase (MTAP), an enzyme essential for the salvage of adenine and methionine, is deficient in a variety of cancers, including acute lymphoblastic leukemia (ALL). 8874207 Human
methylthioadenosine phosphorylase t-cell acute lymphocytic leukemia (t-all) Methylthioadenosine phosphorylase (MTAP) is an important enzyme for the salvage of adenine and methionine and is deficient in a variety of cancers including T-cell acute lymphocytic leukemia (T-ALL). 10197619 Human
methylthioadenosine phosphorylase t cell acute lymphoblastic leukemia Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. 10803528 Human
methylthioadenosine phosphorylase osteosarcoma Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. 11895909 Human
methylthioadenosine phosphorylase t-cell acute lymphoblastic leukemia (t-all) We analyzed the role of methylthioadenosine phosphorylase (MTAP) for chemoselective treatment of T-cell acute lymphoblastic leukemia (T-ALL). 11987241 Human
methylthioadenosine phosphorylase soft tissue sarcomas The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
methylthioadenosine phosphorylase human tumour Regulation of human methylthioadenosine phosphorylase gene by the CBF (CCAAT binding factor)/NF-Y (nuclear factor-Y). hMTAP (human 5'-deoxy-5'-methylthioadenosine phosphorylase) is a key enzyme in the methionine salvage pathway and is frequently 15535799 Human
mtap t-cell acute lymphoblastic leukemias (t-all) Partial or total deletions of the MTAP gene were found in primary T-cell acute lymphoblastic leukemias (T-ALL). 8650244 Human
mtap acute lymphoblastic leukemia (all) Methylthioadenosine phosphorylase (MTAP), an enzyme essential for the salvage of adenine and methionine, is deficient in a variety of cancers, including acute lymphoblastic leukemia (ALL). 8874207 Human
mtap all Because the MTAP gene is located adjacent to the tumor-suppressor gene p16 on chromosome 9p21 and more than 60% of T-cell ALL (T-ALL) patients have deletion in the p16 gene, we examined the status of the MTAP gene in T-ALL patients. 8874207 Human
mtap human pancreatic carcinoma To understand the underlying mechanism, we reintroduced MTAP activity into two p16-, MTAP- cell model systems, the MiaPaCa-2 and PANC-1 human pancreatic carcinoma cell lines, by transfection with MTAP cDNA. 9351982 Human
mtap t-cell acute lymphoblastic leukemia (t-all) Recently, we found frequent deletion of MTAP in T-cell acute lymphoblastic leukemia (T-ALL) patients both at diagnosis and at relapse (A. 9815702 Human
mtap t-cell acute lymphocytic leukemia (t-all) Methylthioadenosine phosphorylase (MTAP) is an important enzyme for the salvage of adenine and methionine and is deficient in a variety of cancers including T-cell acute lymphocytic leukemia (T-ALL). 10197619 Human
mtap t cell acute lymphoblastic leukemia Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. 10803528 Human
mtap cancer In cancer cells that lack methyladenosine phosphorylase (MTAP, required in the salvage pathway), alanosine should deprive such cells (but not normal cells) of de novo synthesized adenosine [277968]. 11763167 Human
mtap glioma In early 1997, patients were being recruited for a phase II pilot efficacy trial of alanosine as a treatment for glioma and NSCLC, since a significant number of these tumor types lack MTAP and, it was hoped, would therefore be sensitive to alanosine [2392 11763167 Human
mtap nsclc In early 1997, patients were being recruited for a phase II pilot efficacy trial of alanosine as a treatment for glioma and NSCLC, since a significant number of these tumor types lack MTAP and, it was hoped, would therefore be sensitive to alanosine [2392 11763167 Human
mtap tumor In early 1997, patients were being recruited for a phase II pilot efficacy trial of alanosine as a treatment for glioma and NSCLC, since a significant number of these tumor types lack MTAP and, it was hoped, would therefore be sensitive to alanosine [2392 11763167 Human
mtap cancer Researchers at UCSD found that some types of cancer lack MTAP, which was responsible for alanosine's previous clinical failure [227466]; phase II trials were being carried out at the university in 1997 [269338]. 11763167 Human
mtap osteosarcoma The aim of this study was to investigate the frequency of molecular alterations in MTAP in osteosarcoma. 11895909 Human
mtap osteosarcoma RESULT: Deletion of at least one MTAP exon was found in 36 of 96 (37.5%) osteosarcoma patient samples and in one of the three cell lines (HOS). 11895909 Human
mtap osteosarcoma Furthermore, in four osteosarcoma patients, an MTAP deletion which was not evident at diagnosis was detected in subsequent tumor samples. 11895909 Human
mtap osteosarcoma CONCLUSIONS: The MTAP gene is commonly deleted in osteosarcoma patient samples, leading to an absence of mRNA and protein expression; these results indicate that inhibitors of de novo purine synthesis or methionine depletion may be effective as treatments 11895909 Human
mtap t-cell acute lymphoblastic leukemia (t-all) We analyzed the role of methylthioadenosine phosphorylase (MTAP) for chemoselective treatment of T-cell acute lymphoblastic leukemia (T-ALL). 11987241 Human
mtap all To evaluate the frequency and extent of deletions in 284 children with ALL, we devised a real-time PCR assay for CDKN2A, CDKN2B exons 1beta and 3, and MTAP gene dosage and validated it by comparison with loss-of-heterozygosity analysis. 12661005 Human
mtap all CDKN2B and/or MTAP co-deletions were highly variable in both T- and B-lineage ALL, making ALL with 9p21 a rather heterogeneous group. 12661005 Human
mtap adenomatous polyposis coli (apc) The MTAP included 21 specific mutations in the adenomatous polyposis coli (APC), p53, and K-ras genes, a microsatellite instability marker (BAT-26), and a marker of abnormal apoptosis (DNA Integrity Assay). 12777192 Human
mtap colorectal cancer (crc) OBJECTIVES: Recent studies have demonstrated good sensitivity and specificity for the detection of colorectal cancer (CRC) utilizing a multitarget DNA assay panel (MTAP) on a single stool specimen. 15233675 Human
mtap soft tissue sarcomas The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
mtap soft tissue sarcoma We used a polyclonal antibody to measure the expression of MTAP in soft tissue sarcoma cell lines and in fresh tumor samples. 15301428 Human
mtap soft tissue sarcoma The expression of MTAP was also not detectable in 3 of the 11 soft tissue sarcoma cell lines (HT-1080, HS42, and M-9 110). 15301428 Human
mtap non-small cell lung cancer [Expression and clinical significance of methylthioadenosine phosphorylase gene in patients with non-small cell lung cancer] OBJECTIVE: To investigate the change of expression of methylthioadenosine phosphorylase (MTAP) gene in patients with non-small cel 15329275 Human
mtap tumor RESULTS: In 11 out of the 15 tumor samples (73.3%) MTAP mRNA was not expressed or expressed only after the additional 5 circulations. 15329275 Human
mtap cancer But the low expression rate of MTAP in intermediate and poorly differentiated lung cancer was significantly higher than that in well-differentiated cancer. 15329275 Human
mtap lung cancer But the low expression rate of MTAP in intermediate and poorly differentiated lung cancer was significantly higher than that in well-differentiated cancer. 15329275 Human
methylthioadenosine phosphorylase adult t cell leukemia Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). 12200696 Human
mtap paraffin-embedded tumors We performed DNA sequence analysis, differential polymerase chain reaction (PCR), and quantitative PCR on DNA from formalin-fixed, paraffin-embedded tumors to evaluate possible alterations of p53, PTEN, K-ras, EGFR, MTAP, and p16 (MTS1/CDKN2) genes. 10329596 Human
mtap diffuse histiocytic lymphoma Although the enzyme deficiency is known to be caused by MTAP gene deletion, human diffuse histiocytic lymphoma cell line DHL-9 without any detectable MTAP activity has been found to possess the intact MTAP gene. 11985785 Human
mtap adult t cell leukemia Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). 12200696 Human
mtap adult t cell leukemia We reported previously that the MTAP gene is deleted in adult T cell leukemia (ATL) cells. 12200696 Human
mtap human soft tissue sarcoma The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of 15301428 Human
mtap periampullary cancer Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. 15662124 Human
mtap biliary cancers Immunolabeling for MTAP was lost in 91 of the 300 (30%) evaluable pancreatic cancers, 9 of 54 (17%) ampullary cancers, 4 of 33 (12%) biliary cancers, and in 1 of 35 (3%) IPMNs. 15662124 Human
methylthioadenosine phosphorylase hepatocellular carcinoma Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. 16081515 Human
methylthioadenosine phosphorylase other cancers The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthe 16234352 Human
methylthioadenosine phosphorylase t-cell acute lymphoblastic leukemia (t-all) The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthe 16234352 Human
methylthioadenosine phosphorylase tumor Methylthioadenosine is formed during the biosynthesis of spermidine and of spermine and is metabolized by methylthioadenosine phosphorylase, an enzyme missing in several tumor cell lines. 16260735 Human
methylthioadenosine phosphorylase biliary tract cancers Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. 16373701 Human
methylthioadenosine phosphorylase cancers The p16(INK4A)/CDKN2A gene on chromosome 9p21 is a site of frequent allelic loss in human cancers, and in a subset of cases, homozygous deletions at this locus encompass the telomeric methylthioadenosine phosphorylase (MTAP) gene. 16373701 Human
methylthioadenosine phosphorylase skin tumors Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors. 16618867 Human
methylthioadenosine phosphorylase skin tumors BACKGROUND: Using tissue microarrays, we investigated whether methylthioadenosine phosphorylase (MTAP) protein expression is associated with clinicopathologic variables in benign and malignant melanocytic skin tumors. 16618867 Human
methylthioadenosine phosphorylase chondrosarcomas Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas. 16631464 Human
methylthioadenosine phosphorylase mantle cell lymphoma Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. 16778103 Human
methylthioadenosine phosphorylase mantle cell lymphoma (mcl) PURPOSE: To determine the methylthioadenosine phosphorylase (MTAP) gene alterations in mantle cell lymphoma (MCL) and to investigate whether the targeted inactivation of the alternative de novo AMP synthesis pathway may be a useful therapeutic strategy in 16778103 Human
methylthioadenosine phosphorylase tumors PURPOSE: To determine the methylthioadenosine phosphorylase (MTAP) gene alterations in mantle cell lymphoma (MCL) and to investigate whether the targeted inactivation of the alternative de novo AMP synthesis pathway may be a useful therapeutic strategy in 16778103 Human
mtap cancers MTAP Homozygous Deletion: An Achilles Heel of Human Cancers Ready for Clinical Use? 15876862 Human
mtap hepatocellular carcinoma Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. 16081515 Human
mtap hepatocellular carcinoma (hcc) The aim of this study was to analyse MTAP expression in hepatocellular carcinoma (HCC) and to get an insight into the regulation and functional role of MTAP in hepatocancerogenesis. 16081515 Human
mtap other cancers Among candidate hypermethylated genes in cancer-derived lines, there were eight (CD44, CDKN1A, ESR1, PLAU, RARB, SFN, TNFRSF6, and TSPY) previously observed in prostate cancer and 13 previously known methylation targets in other cancers (ARHI, bcl-2, BRCA 16207477 Human
mtap prostate cancer Among candidate hypermethylated genes in cancer-derived lines, there were eight (CD44, CDKN1A, ESR1, PLAU, RARB, SFN, TNFRSF6, and TSPY) previously observed in prostate cancer and 13 previously known methylation targets in other cancers (ARHI, bcl-2, BRCA 16207477 Human
mtap barrett's esophagus Complete loss of MTAP and p16 was seen in 4 of 25 (16%) patients with Barrett's esophagus, 4 of 18 (22%) with low-grade dysplasia, 5 of 39 (13%) with high-grade dysplasia, 17 of 78 (22%) with invasive adenocarcinoma, and 8 of 36 (22%) of metastases. 16224217 Human
mtap invasive adenocarcinoma Complete loss of MTAP and p16 was seen in 4 of 25 (16%) patients with Barrett's esophagus, 4 of 18 (22%) with low-grade dysplasia, 5 of 39 (13%) with high-grade dysplasia, 17 of 78 (22%) with invasive adenocarcinoma, and 8 of 36 (22%) of metastases. 16224217 Human
mtap metastases Complete loss of MTAP and p16 was seen in 4 of 25 (16%) patients with Barrett's esophagus, 4 of 18 (22%) with low-grade dysplasia, 5 of 39 (13%) with high-grade dysplasia, 17 of 78 (22%) with invasive adenocarcinoma, and 8 of 36 (22%) of metastases. 16224217 Human
mtap esophageal adenocarcinoma There were 7 cases of esophageal adenocarcinoma with loss of both MTAP and p16 for which precursor lesions were available. 16224217 Human
mtap gastric adenocarcinoma Lack of MTAP and p16 expression was seen in 11 of 106 (10%) cases of gastric adenocarcinoma. 16224217 Human
mtap gastric cancers No precursor lesions were available from the gastric cancers that had loss of both MTAP and p16. 16224217 Human
mtap hyperplastic polyps Two benign gastric hyperplastic polyps also had intact p16 and MTAP. 16224217 Human
mtap other cancers The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthe 16234352 Human
mtap t-cell acute lymphoblastic leukemia (t-all) The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthe 16234352 Human
mtap t-all We demonstrate that MTAP- T-ALL cells obtained at relapse are as sensitive to L-alanosine toxicity as diagnosis samples. 16234352 Human
mtap t-all EFA at 20 microM or less rescued primary MTAP+ T-ALL cells and normal lymphocytes from L-alanosine toxicity. 16234352 Human
mtap cancers The p16(INK4A)/CDKN2A gene on chromosome 9p21 is a site of frequent allelic loss in human cancers, and in a subset of cases, homozygous deletions at this locus encompass the telomeric methylthioadenosine phosphorylase (MTAP) gene. 16373701 Human
mtap cancers The MTAP gene product is the principal enzyme involved in purine synthesis via the salvage pathway, such that MTAP-negative cancers are solely dependent on de novo purine synthesis mechanisms. 16373701 Human
mtap biliary tract cancers In this study, we determine that 10 of 28 (35%) biliary tract cancers show complete lack of Mtap protein expression. 16373701 Human
mtap biliary tract cancers Inhibitors of de novo purine synthesis can be a potential mechanism-based strategy for treatment of biliary tract cancers, one third of which show complete loss of MTAP function. 16373701 Human
mtap skin tumors BACKGROUND: Using tissue microarrays, we investigated whether methylthioadenosine phosphorylase (MTAP) protein expression is associated with clinicopathologic variables in benign and malignant melanocytic skin tumors. 16618867 Human
mtap melanoma No difference was noted in MTAP expression between primary malignant melanomas and melanoma metastases. 16618867 Human
mtap metastases No difference was noted in MTAP expression between primary malignant melanomas and melanoma metastases. 16618867 Human
mtap primary malignant melanomas No difference was noted in MTAP expression between primary malignant melanomas and melanoma metastases. 16618867 Human
mtap primary malignant melanomas In primary malignant melanomas, a Ki67-labeling index less than 5% was associated with MTAP expression (P = .04), suggesting that loss of MTAP expression is associated with proliferation. 16618867 Human
mtap skin metastases Lymph node metastases demonstrated significantly higher MTAP expression compared with skin metastases (P = .01). 16618867 Human
mtap head and neck squamous cell carcinoma Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. 16618910 Human
mtap head and neck cancer The frequency and precise loss of CDKN2B(INK4b), CDKN2A(ARF, INK4a), and MTAP in the prognosis of 9p21-deleted HNSCC may provide impetus for use of these targets as therapeutic biomarkers in head and neck cancer. 16618910 Human
mtap chondrosarcoma Based on these observations, we investigated the frequency of MTAP deletions in conventional, grade II chondrosarcomas by fluorescence in situ hybridization (FISH) analysis: 23 conventional, grade II chondrosarcoma patient samples from the Cleveland Clini 16631464 Human
mtap chondrosarcomas Based on these observations, we investigated the frequency of MTAP deletions in conventional, grade II chondrosarcomas by fluorescence in situ hybridization (FISH) analysis: 23 conventional, grade II chondrosarcoma patient samples from the Cleveland Clini 16631464 Human
mtap mantle cell lymphoma (mcl) PURPOSE: To determine the methylthioadenosine phosphorylase (MTAP) gene alterations in mantle cell lymphoma (MCL) and to investigate whether the targeted inactivation of the alternative de novo AMP synthesis pathway may be a useful therapeutic strategy in 16778103 Human
mtap tumors PURPOSE: To determine the methylthioadenosine phosphorylase (MTAP) gene alterations in mantle cell lymphoma (MCL) and to investigate whether the targeted inactivation of the alternative de novo AMP synthesis pathway may be a useful therapeutic strategy in 16778103 Human
mtap mcl EXPERIMENTAL DESIGN: MTAP gene deletion and protein expression were studied in 64 and 52 primary MCL, respectively, and the results were correlated with clinical behavior. 16778103 Human
mtap mcl Five MCL cell lines were analyzed for MTAP expression and for the in vitro sensitivity to l-alanosine, an inhibitor of adenylosuccinate synthetase, and hence de novo AMP synthesis. 16778103 Human
mtap negative tumors Six of these MTAP negative tumors and Granta 519 cell line had a codeletion of MTAP and p16 genes; one case showed a deletion of MTAP, but not p16, and one tumor had no deletions in neither of these genes. 16778103 Human
mtap tumor Six of these MTAP negative tumors and Granta 519 cell line had a codeletion of MTAP and p16 genes; one case showed a deletion of MTAP, but not p16, and one tumor had no deletions in neither of these genes. 16778103 Human
mtap mcl Patients with MTAP deletions had a significant shorter overall survival (mean, 16.1 months) than patients with wild-type MTAP (mean, 63.6 months; P < 0.0001). l-Alanosine induced cytotoxicity and activation of the intrinsic mitochondrial-dependent apoptot 16778103 Human
mtap b-lineage acute lymphoblastic leukemia The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. 16818274 Human
mtap all Bi-allelic CDKN2B and MTAP co-inactivation were found in 36 (16%) and 24 (11%) of patients, respectively, and did not influence the 6-year event-free survival rate either, even when the analysis was restricted to CDKN2A inactivated ALL. 16818274 Human
mtap all INTERPRETATION AND CONCLUSIONS: In this study of 227 cases of childhood B-lineage ALL, inactivation of CDKN2A, CDKN2B and MTAP did not influences the patients' outcome. 16818274 Human
mtap biliary cancer In vitro analysis using a selective inhibitor of the de novo purine synthesis pathway, l-alanosine, shows robust growth inhibition in MTAP-negative biliary cancer cell lines CAK-1 and GBD-1 accompanied by striking depletion of intracellular ATP and failur 16373701 Human
mtap lymph node metastases Lymph node metastases demonstrated significantly higher MTAP expression compared with skin metastases (P = .01). 16618867 Human
mesado phosphorylase lymphoma In the present experiments, we have analyzed the effects of MeSAdo on diphthamide synthesis in a MeSAdo phosphorylase-deficient mutant murine lymphoma cell line (R1.1, clone H3). 3091083 Mouse
mesado phosphorylase lymphoma To test this hypothesis, we have analyzed the effects of DFMO, in combination with MeSAdo, on polyamine synthesis and growth in a MeSAdo phosphorylase-deficient murine lymphoma cell line (R1.1-H), and a MeSAdo resistant mutant (R1.1-H3). 3102048 Human
mesado phosphorylase tumors It is conceivable that MeSAdo, or related nucleosides, may potentiate the cytostatic effects of DFMO toward MeSAdo phosphorylase-deficient tumors. 3102048 Human
mesado phosphorylase lung cancer We also tested the effects of MeSAdo phosphorylase-selective chemotherapy on the in vitro growth of enzyme-positive and enzyme-negative lung cancer cell lines. 8382555 Human
mesado phosphorylase human promyelocytic leukemia In preliminary studies, HIPA inhibited MeSAdo phosphorylase in intact HL-60 human promyelocytic leukemia cells, as it limited the incorporation of [8-14C]MeSAdo into cellular adenine nucleotide pools. 2125222 Human
mesado phosphorylase cancer Some of these novel MeSAdo phosphorylase inhibitors may have a role in cancer chemotherapy as potentiators of agents that block purine de novo synthesis, e.g. antifolates and 6-methylmercaptopurine ribonucleoside. 2125222 Human
methylthioadenosine phosphorylase lymphoma Heterogeneity of the toxic mechanisms of methylthioadenosine in methylthioadenosine phosphorylase deficient murine lymphoma cells. 2514586 Mouse
methylthioadenosine phosphorylase leukemia 5'-deoxy-5'-methylthioadenosine phosphorylase deficiency in leukemia: genetics and biochemical aspects. 3094332 Human
methylthioadenosine phosphorylase lymphoma Synergistic inhibition of polyamine synthesis and growth by difluoromethylornithine plus methylthioadenosine in methylthioadenosine phosphorylase-deficient murine lymphoma cells. 3102048 Human
methylthioadenosine phosphorylase lymphoma To determine the effects of the loss of this enzyme on cell growth and metabolism, we selected two methylthioadenosine phosphorylase-deficient mutant clones of the transplantable murine T lymphoma cell line R1.1. 6408072 Mouse
methylthioadenosine phosphorylase promyelocytic leukemia 5'-Deoxy-5'-methylthioadenosine and 5'-deoxy-5'-methylthioinosine, which are metabolized to the methionine precursor, 5-methylthioribose-1-phosphate, by 5'-deoxy-5'-methylthioadenosine phosphorylase and purine nucleoside phos 6411330 Human
methylthioadenosine phosphorylase t-cell leukemia CCRF-CEM T-cell leukemia cells, which lack 5'-deoxy-5'-methylthioadenosine phosphorylase, convert 5'-deoxy-5'-methylthioinosine (but not 5'-deoxy-5'-methylthioadenosine) to methionine; this conversion is blocked by purine nuc 6411330 Human
methylthioadenosine phosphorylase lymphoma The availability of a human lymphoma cell line deficient in adenosine deaminase, adenosine kinase and methylthioadenosine phosphorylase enabled us to compare the effects of nucleoside transport inhibitors on the excretion of endogenously generated adenosi 6428410 Human
methylthioadenosine phosphorylase leukemia Cells from 20 patients with leukemia and 9 with solid tumors were assayed for the enzyme methylthioadenosine phosphorylase, which function in both purine and polyamine metabolism in rapidly dividing cells. 6814551 Human
methylthioadenosine phosphorylase leukemias In contrast, other leukemias of similar antigenic phenotype, as well as normal peripheral blood lymphocytes, thymic lymphocytes, and normal bone marrow cells, had substantial methylthioadenosine phosphorylase activity. 6814551 Human
methylthioadenosine phosphorylase multiple tumor 5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. 7898924 Human
methylthioadenosine phosphorylase human tumors Enzyme deficiency and tumor suppressor genes: absence of 5'-deoxy-5'-methylthioadenosine phosphorylase in human tumors. 8172020 Human
methylthioadenosine phosphorylase tumor Enzyme deficiency and tumor suppressor genes: absence of 5'-deoxy-5'-methylthioadenosine phosphorylase in human tumors. 8172020 Human
methylthioadenosine phosphorylase leukemias In this study, 27 malignant cell lines, including leukemias, gliomas, and lung and bladder carcinomas were screened for homozygous deletions of the putative tumor suppressor gene p16 (MTS1/CDK4I/CDKN2) and other markers within the chromosome 9p21 region; 8616780 Human
methylthioadenosine phosphorylase malignancy Deficiency of 5'-deoxy-5'-methylthioadenosine phosphorylase activity in malignancy. 1736901 Human
methylthioadenosine phosphorylase lymphomas Abnormalities of chromosome 9p have been reported in human leukemias and lymphomas, and in cell lines lacking the enzyme methylthioadenosine phosphorylase. 1879830 Human
methylthioadenosine phosphorylase lymphomas A complete deficiency of methylthioadenosine phosphorylase has been reported in some human leukemias and lymphomas and in a few solid tumors. 1904005 Human
5'-methylthioadenosine phosphorylase leukemias Using two 5'-methylthioadenosine phosphorylase-negative leukemias, we have for the first time been able to measure the synthesis and biological effects of 5'-methylthioadenosine (MTA) in intact mammalian tumor cells. 6781742 Human
5'-methylthioadenosine phosphorylase tumor Using two 5'-methylthioadenosine phosphorylase-negative leukemias, we have for the first time been able to measure the synthesis and biological effects of 5'-methylthioadenosine (MTA) in intact mammalian tumor cells. 6781742 Human
mtap leukemias In this study, 27 malignant cell lines, including leukemias, gliomas, and lung and bladder carcinomas were screened for homozygous deletions of the putative tumor suppressor gene p16 (MTS1/CDK4I/CDKN2) and other markers within the chromosome 9p21 region; 8616780 Human
mtap oncogenic Thus the MTAP loss in malignant cells may be an example of gene deletion chemoselectivity, in which genetic deletions that occur as part of the oncogenic process render these cells more sensitive to particular anticancer agents than normal cells, which ha 8640765 Human
mtap cancer It has been suggested that this metabolic difference between normal and cancer cells may be exploited to selectively treat MTAP-negative cancers by inhibiting de novo purine synthesis and by depleting L-methionine. 8971171 Human
mtap cancers It has been suggested that this metabolic difference between normal and cancer cells may be exploited to selectively treat MTAP-negative cancers by inhibiting de novo purine synthesis and by depleting L-methionine. 8971171 Human
mtap cancers Inhibition of de novo purine synthesis, combined with methionine depletion in the presence of methylthioadenosine, is a highly selective treatment for MTAP-negative cancers. 8971171 Human
mtap lymphoma Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. 9591637 Human
methylthioadenosine phosphorylase melanoma This was not seen in the patients with MTAP-negative tumors.Conclusion Methylthioadenosine phosphorylase protein expression may be a predictive marker of interferon therapy resistance in patients with melanoma and disease progression. 16618867 Human
mtap melanoma This was not seen in the patients with MTAP-negative tumors.Conclusion Methylthioadenosine phosphorylase protein expression may be a predictive marker of interferon therapy resistance in patients with melanoma and disease progression. 16618867 Human
methylthioadenosine phosphorylase t-cell acute lymphoblastic leukemia Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. 10197619 Human
methylthioadenosine phosphorylase osteosarcoma Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. 11895909 Human
methylthioadenosine phosphorylase human tumor The human methylthioadenosine phosphorylase (MTAP) gene is located on 9p21 and is frequently homozygously deleted, along with p16(cdkN2a/ARF), in a wide variety of human tumors and human tumor-derived cell lines. 12438261 Human
methylthioadenosine phosphorylase lymphoma Molecular characterization of 5'-deoxy-5'-methylthioadenosine phosphorylase-deficient mutant clones of murine lymphoma cell line R1.1. 5'-Deoxy-5'-methylthioadenosine phosphorylase (MTAP), the polyamine and purine metabolic enzyme, is 12824877 Human
methylthioadenosine phosphorylase lymphoma Methylthioadenosine phosphorylase gene is silenced by promoter hypermethylation in human lymphoma cell line DHL-9: another mechanism of enzyme deficiency. 15753993 Human
methylthioadenosine phosphorylase t-cell acute lymphoblastic leukemia EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. 16234352 Human
methylthioadenosine phosphorylase mesothelioma Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma. 17041099 Human
mtap t-all We now report that MTAP-primary T-ALL cells are more sensitive to the toxicity of L-alanosine, an inhibitor of de novo AMP synthesis, than are MTAP+ primary T-ALL cells. 10197619 Human
mtap t-all As measured by [3H]thymidine incorporation, DNA synthesis in all seven MTAP-primary T-ALL cells was inhibited by L-alanosine with a mean IC50 of 4.8+/-5.3 ILM (range, 0.3-11.3 microM). 10197619 Human
mtap all Furthermore, normal lymphocytes and MTAP+ primary T-ALL cells were rescued from L-alanosine toxicity by the MTAP substrate 5'-deoxyadenosine, but MTAP-T-ALL cells were not. 10197619 Human
mtap t-all Thus, our results support the use of L-alanosine alone or in combination with a salvage agent as a MTAP-selective therapy and therefore lay the foundation for the initiation of clinical trials for the treatment of T-ALL and other MTAP-deficient malignanci 10197619 Human
mtap tumorigenesis Thus, our data suggest that, except for p15/16 and MTAP gene, there were at least two candidate tumor suppressor genes located at chromosome 9p, and that the alteration of these genes is associated with the tumorigenesis of oral SCC. 10226521 Human
mtap osteosarcoma The aim of this study was to investigate the frequency of molecular alterations in MTAP in osteosarcoma. 11895909 Human
mtap osteosarcoma RESULT: Deletion of at least one MTAP exon was found in 36 of 96 (37.5%) osteosarcoma patient samples and in one of the three cell lines (HOS). 11895909 Human
mtap osteosarcoma Furthermore, in four osteosarcoma patients, an MTAP deletion which was not evident at diagnosis was detected in subsequent tumor samples. 11895909 Human
mtap osteosarcoma CONCLUSIONS: The MTAP gene is commonly deleted in osteosarcoma patient samples, leading to an absence of mRNA and protein expression; these results indicate that inhibitors of de novo purine synthesis or methionine depletion may be effective as treatments 11895909 Human
mtap tumor The chemoselective effect of antimetabolites in MTAP-deleted tumor cells may, however, be compensated by the development of drug resistance. 11987241 Human
mtap t-all We conclude that ALA may be more suitable than MTX or TMX for MTAP-mediated chemoselective treatment of T-ALL. 11987241 Human
mtap human tumor The human methylthioadenosine phosphorylase (MTAP) gene is located on 9p21 and is frequently homozygously deleted, along with p16(cdkN2a/ARF), in a wide variety of human tumors and human tumor-derived cell lines. 12438261 Human
mtap tumor In addition, MTAP-expressing cells are suppressed for tumor formation when implanted into SCID mice. 12438261 Human
mtap lymphoma Molecular characterization of 5'-deoxy-5'-methylthioadenosine phosphorylase-deficient mutant clones of murine lymphoma cell line R1.1. 5'-Deoxy-5'-methylthioadenosine phosphorylase (MTAP), the polyamine and purine metabolic enzyme, is 12824877 Human
mtap lymphoma MTAP-deficient mutants were previously selected from murine lymphoma cell line R1.1 that contains abundant MTAP activity, to analyze the metabolic consequences of MTAP deficiency. 12824877 Human
mtap human tumor The addition of the penultimate salvage pathway compound 4-methylthio-2-oxobutanoic acid represses ODC levels in both MTAP-deleted yeast and human tumor cell lines, indicating that 4-methylthio-2-oxobutanoic acid acts as a negative regulator of polyamine 14506228 Human
mtap hepatocarcinogenesis Given the recently proposed tumor suppressor activity of MTAP, our observations can be relevant to the elucidation of the molecular mechanisms of multistep hepatocarcinogenesis. 15511635 Human
mtap adenocarcinomas Result: MTAP activity was 2.8-fold reduced in adenocarcinomas and 6.3-fold reduced in neuroendocrine tumors compared with control pancreas. 15534104 Human
mtap pancreatic adenocarcinoma We also show that inhibition of ODC by difluoromethylornithine caused decreased cell growth and increased apoptosis in two MTAP-deleted pancreatic adenocarcinoma-derived cell lines. 15534104 Human
mtap cis To understand the mechanism of the transcriptional regulation of the MTAP gene, we have cloned the 1.29 kb fragment of the hMTAP promoter and identified cis-acting regulatory sequences using a luciferase reporter gene assay. 15535799 Human
mtap neoplasms All neoplasms with loss of MTAP labeling also demonstrated loss of p16 labeling. 15662124 Human
mtap neoplasms These results suggest that MTAP expression is lost in approximately 30% of infiltrating pancreatic cancers and in a lower percentage of other periampullary neoplasms, that this loss is the result of homozygous deletions encompassing both the MTAP and p16I 15662124 Human
mtap lymphoma Although this enzyme deficiency was reportedly caused by partial or total deletion of the MTAP gene, human MTAP-deficient lymphoma cell line DHL-9 has the intact MTAP gene. 15753993 Human
mtap hcc Compared with primary human hepatocytes MTAP expression was markedly downregulated in three different HCC cell lines as determined by real-time PCR and western blotting. 16081515 Human
mtap hcc Reduced MTAP-expression was confirmed in vivo in HCC compared with non-cancerous liver tissue on both mRNA and protein levels. 16081515 Human
mtap hcc To study the functional relevance of the downregulated MTAP expression in HCC, MTAP expression was re-induced in HCC cell lines by stable transfection. 16081515 Human
mtap hcc In conclusion, our results suggest a functional role of MTAP inactivation in HCC development and invasiveness. 16081515 Human
mtap cancer Among candidate hypermethylated genes in cancer-derived lines, there were eight (CD44, CDKN1A, ESR1, PLAU, RARB, SFN, TNFRSF6, and TSPY) previously observed in prostate cancer and 13 previously known methylation targets in other cancers (ARHI, bcl-2, BRCA 16207477 Human
mtap carcinogenesis Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. 16224217 Human
mtap adenocarcinomas This loss of MTAP during 9p21 homozygous deletion might be exploited therapeutically using de novo purine synthesis antimetabolites to treat a subset of invasive gastroesophageal adenocarcinomas and esophageal precursor lesions. 16224217 Human
mtap melanomas Among 26 patients with MTAP-positive melanomas and tumor recurrence, 18 patients who received interferon therapy had a significant benefit compared with 8 patients who did not receive interferon therapy (P = .009). 16618867 Human
mtap tumor Among 26 patients with MTAP-positive melanomas and tumor recurrence, 18 patients who received interferon therapy had a significant benefit compared with 8 patients who did not receive interferon therapy (P = .009). 16618867 Human
mtap tumors This was not seen in the patients with MTAP-negative tumors.Conclusion Methylthioadenosine phosphorylase protein expression may be a predictive marker of interferon therapy resistance in patients with melanoma and disease progression. 16618867 Human
mtap hnscc The frequency and precise loss of CDKN2B(INK4b), CDKN2A(ARF, INK4a), and MTAP in the prognosis of 9p21-deleted HNSCC may provide impetus for use of these targets as therapeutic biomarkers in head and neck cancer. 16618910 Human
mtap solid tumor Homozygous deletions of MTAP have been reported in hematologic and solid tumor malignancies. 16631464 Human
mtap mcl CONCLUSIONS: MTAP gene deletion and lack of protein expression are associated with poor prognosis in MCL and might identify patients who might benefit from treatment with de novo AMP synthesis pathway-targeted therapies. 16778103 Human
mtap leukemia Inactivation of CDKN2A, CDKN2B and MTAP in childhood B-lineage acute lymphobastic leukemia. 16818264 Human
mtap mesothelioma Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma. 17041099 Human
mtap mesothelioma The current study addresses the effect of MTAP on pemetrexed activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines. 17041099 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.